

KORIL approves Collect's grant application for stem cells therapy

18 December 2018 | News

The agreement will potentially enhance and accelerate the development of Collect's ApoGraft Technology Platform.



Collect Biotechnology Ltd., a developer of a novel stem cell production technology, announced that KORIL-RDF, has approved Collect's grant application, submitted with Cell2in, a Korean cell therapy company with whom a collaboration agreement was signed recently.

The agreement will potentially enhance and accelerate the development of Collect's ApoGraft Technology Platform. In addition, the combination of the two technologies may result in a synergic effect on stem cell expansion, and open new potential applications.

According to the agreement, Collect will use Cell2in proprietary FreSHtracer technology for the functional identification of stem cells. Both companies will collaborate on a proof-of-concept of combining technologies in order to significantly improve stem cells selection process. Upon potentially successful results, both companies plan to broaden their collaboration to provide a combined solution that will benefit multiple stem cell therapy products covering a wide range of diseases.